n Southern African Journal of HIV Medicine - The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis : case study - HIV and the kidneys




The South African public sector antiretroviral treatment (ART) guidelines have recently been changed to include tenofovir in the first-line regimen. Injectable drugs from the aminoglycoside class are part of the intensive phase of regimen 2 tuberculosis (TB) treatment and the multidrug-resistant (MDR) TB treatment regimen in the South African TB programme. We wish to draw the attention of clinicians managing patients with HIV-associated TB to the potential dangers of concurrent administration of these drugs. We present two illustrative cases.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error